Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Go back to Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma| Merck & Co. (NYSE: MRK) | Delayed: 148.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.46 | 52 Week High | $65.46 | |||
| Open | $148.46 | 52 Week Low | $47.97 | |||
| Day High | $148.46 | P/E | 100.99 | |||
| Day Low | $148.46 | EPS | $1.47 | |||
| Volume | 4,314 | |||||
